IRCT20151227025726N14招募中3 期
Evaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patients
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Laboratory confirmed COVID-19 with RT-PCR
- •Age over 18 years old
- •Oxygen saturation < 93%
- •Fever more than 72 hours before admission
- •Bilateral pulmonary infiltration
排除标准
- •Chronic kidney Disease
- •Acute kidney Injury
- •Pregnancy or breastfeeding
- •Drug allergy history
- •Chronic liver disease
- •Mild phase of COVID-19
- •Critical phase of COVID-19
研究者
相似试验
招募中
3 期
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60
招募中
3 期
The evaluation of efficacy of Favipiravir in patients with mild to moderate COVID-19IRCT20201005048936N1Dr. Abidi pharmacutical Co.126
招募中
2 期
Effectiveness of favipiravir in comparison with Tenofovir Alafenamid in patients with COVID-19COVID-19.COVID-19U07.1IRCT20150808023559N23Ardabil University of Medical Sciences100
招募中
3 期
The therapeutic effect of Favipiravir in COVID-19 patientsIRCT20211004052664N1Shahid Beheshti University of Medical Sciences80
已完成
不适用
The Real-world Clinical Outcomes of Favipiravir Treatment in Mild to Moderate COVID-19 Patients in Single Outpatient Visit Followed by Home Isolation: a Multicenter, case-control StudyTCTR20221113004Chulabhorn Royal Academy1,037